Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SL Science HoldingSLBT +24.39%12 Gross Margin % is 36.14% as of Dec. 2025, which is 37% below its 10-year median of 57.46. GuruFocus rates SLBT with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 734 Biotechnology companies, SL Science Holding ranks worse than 72.48% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
SL Science Holding had a gross margin of 36.14% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
SL Science Holding Gross Margin % Related Terms
SL Science Holding Gross Margin % Historical Data
* Premium members only.
The historical data trend for SL Science Holding's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SL Science Holding Gross Margin % Chart
SL Science Holding Annual Data
Trend
Dec23
Dec24
Dec25
Gross Margin %
83.96
57.46
35.28
SL Science Holding Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Gross Margin %
0.00
87.16
40.50
34.46
36.14
SLBT vs DMRA, BCAX, TYRA: Gross Margin % Comparison
For the Biotechnology subindustry, SL Science Holding's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SL Science Holding Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SL Science Holding's Gross Margin % distribution charts can be found below:
* The bar in red indicates where SL Science Holding's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
SL Science Holding (SLBT) has a Gross Margin % of 36.14% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on SL Science Holding and its competitors. This is 37% below median its historical median of 57.46. Over the past decade, SL Science Holding's Gross Margin % has ranged from 35.28 to 83.96. According to the industry distribution chart, SL Science Holding ranks #532 out of 734 companies in the Biotechnology industry, placing it in the top 72.5%.
Is SL Science Holding's Gross Margin % too high?
SL Science Holding's current Gross Margin % of 36.14% is 37% below median its 10-year median of 57.46. Over the past 10 years, this metric has ranged from a low of 35.28 to a high of 83.96. The Biotechnology industry median Gross Margin % is 60.91. SL Science Holding's value of 36.14% is 40.7% below this industry median. Based on the distribution chart, SL Science Holding ranks #532 out of 734 companies in the Biotechnology industry, which is below the industry midpoint. Overall, SL Science Holding has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SL Science Holding's Gross Margin % compare to DMRA and BCAX?
According to the Biotechnology industry distribution chart, SL Science Holding ranks #532 out of 734 companies for Gross Margin %. This places SL Science Holding in the lower half of its industry. The industry median Gross Margin % is 60.91. SL Science Holding's value of 36.14% is 40.7% below this benchmark. Historically, SL Science Holding's own Gross Margin % has ranged from 35.28 to 83.96 over the past decade. While the company's 10-year median is 57.46 vs. the industry median of 60.91, SL Science Holding has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SL Science Holding's current Gross Margin % of 36.14% is 40.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on SL Science Holding and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SL Science Holding's current Gross Margin % is 36.14%, which is 37% below median its own 10-year median of 57.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SL Science Holding stock overvalued right now?
SL Science Holding (SLBT) has a current Gross Margin % of 36.14%. The current Gross Margin % is 36.14%, which is 37% below median its 10-year median of 57.46 and 40.7% below the Biotechnology industry median of 60.91. SL Science Holding's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For SL Science Holding (SLBT), the current Gross Margin % is 36.14% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
12GF Score
Get the complete analysis for SLBT
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLBT has been successfully added to your 
